Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Luis Paz‐Ares, Mehdi Shahidi et al.|The Lancet Oncology|2016Cited by 1.2k
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in ChinaYuankai Shi, Jingwen Wang, Bo Jia et al.|Journal of Hematology & Oncology|2017Cited by 256
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Peng Liu, Hang Su et al.|The Lancet Haematology|2019Cited by 248
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in ChinaYuankai Shi, Yan Sun, Ying Han et al.|Chinese Journal of Cancer Research|2019Cited by 126
Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment ResponsesYuankai Shi, Yinghong Zhang, Xiaoqing Liu et al.|Clinical Cancer Research|2014Cited by 115